These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17133204)

  • 41. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.
    Lucas GM; Cheever LW; Chaisson RE; Moore RD
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):251-9. PubMed ID: 11464144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital.
    Santos CQ; Adeyemi O; Tenorio AR
    AIDS Care; 2006 Oct; 18(7):808-11. PubMed ID: 16971292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
    Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
    AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
    Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
    AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Utility of Pharmacy-Based Adherence Measurement in Predicting Virologic Outcomes in an Adult HIV-Infected Cohort in Jos, North Central Nigeria.
    Abah IO; Ojeh VB; Musa J; Ugoagwu P; Agaba PA; Agbaji O; Okonkwo P
    J Int Assoc Provid AIDS Care; 2016; 15(1):77-83. PubMed ID: 24963086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
    Caseiro MM; Nelson M; Diaz RS; Gathe J; de Andrade Neto JL; Slim J; Solano A; Netto EM; Mak C; Shen J; Greaves W; Dunkle LM; Vilchez RA; Zeinecker J
    J Infect; 2012 Oct; 65(4):326-35. PubMed ID: 22634184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
    Walmsley SL; Thorne A; Loutfy MR; LaPierre N; MacLeod J; Harrigan R; Trottier B; Conway B; Hay JR; Singer J; Zarowny D
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):418-25. PubMed ID: 17468667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California.
    Garland WH; Wohl AR; Valencia R; Witt MD; Squires K; Kovacs A; Larsen R; Potterat N; Anthony MN; Hader S; Weidle PJ
    AIDS Care; 2007 Feb; 19(2):159-67. PubMed ID: 17364394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.
    Kempf DJ; Rode RA; Xu Y; Sun E; Heath-Chiozzi ME; Valdes J; Japour AJ; Danner S; Boucher C; Molla A; Leonard JM
    AIDS; 1998 Mar; 12(5):F9-14. PubMed ID: 9543434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
    Ungsedhapand C; Kroon ED; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):116-23. PubMed ID: 11404532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy.
    Pilcher CD; Miller WC; Beatty ZA; Eron JJ
    AIDS; 1999 Jul; 13(11):1337-42. PubMed ID: 10449286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
    Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K
    Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.